Fourth Quarter and FY2025 Preliminary and Unaudited Results February 10, 2026 Forward-Looking Statements and Risk Factors Certain statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, particularly those regarding our 2025 Financial Guidance. Such forward-looking statements are subject to numerous assumptions, risks and uncertainties that could cause actual results to differ materially from those described in those stateme ...

Core Insights - Under Armour reported a third-quarter revenue decrease of 5% to $1.33 billion, with a 10% decline in North America and a 3% increase in international revenue [6][10]. - The company experienced an operating loss of $150 million, with adjusted operating income of $26 million after excluding certain expenses [6][10]. - The CEO expressed optimism about the company's transformation and brand momentum, indicating that the December quarter marked a challenging phase but expects greater stability moving forward [2][6]. Financial Performance - Revenue decreased 5% to $1.33 billion, with North America revenue down 10% to $757 million and international revenue up 3% to $577 million [6][10]. - Gross margin declined by 310 basis points to 44.4%, primarily due to higher tariffs and pricing headwinds [6][10]. - Selling, general and administrative (SG&A) expenses increased 4% to $665 million, but adjusted SG&A declined 7% to $563 million when excluding litigation and transformation expenses [6][10]. Restructuring and Transformation - The company is undergoing a restructuring plan expected to cost up to $255 million, with $178 million recorded in restructuring and impairment charges to date [7][10]. - The restructuring plan aims to improve financial and operational efficiency, with a focus on better products and disciplined market presence [2][7]. Outlook - For fiscal 2026, revenue is expected to decline approximately 4%, with a projected operating loss of around $154 million [10]. - Adjusted diluted earnings per share are anticipated to range from $0.10 to $0.11, compared to a previous outlook of $0.03 to $0.05 [10]. Inventory and Liquidity - Inventory decreased by 2% to $1.1 billion, indicating improved inventory management [6][10]. - Cash and cash equivalents totaled $465 million at quarter-end, with no borrowings under the $1.1 billion revolving credit facility [6][10].

Benchmark Electronics Fourth Quarter and Fiscal Year 2025 Results February 3rd, 2026 Forward-Looking Statements This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts and may include words such as "anticipate," "believe," "intend," "plan," "projec ...

Business Overview - Concentra is the largest provider of occupational health services in the United States by number of locations[7] - The company cares for an average of over 52,000 patients each business day[7] - Concentra serves approximately 200,000 employer customers[7] - The company treats approximately 1 in every 4 injuries that occur within the U S workplace[12] - Concentra has over 1,000 total locations[12] Financial Performance - Concentra's TTM Revenue is $21 billion[8] - The company's TTM Adjusted EBITDA is $414 million[8] - Concentra's TTM Adjusted EBITDA margin is 198%[8] - The company's TTM free cash flow is $176 million[11] - Concentra's revenue from the largest employer customer is less than 3%[8]

2026 JP Morgan Healthcare Conference Damien McDonald Chief Executive Officer Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Presentation Title is set in ALL CAPS Short description is set in sentence case This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, g ...

Forward-Looking Statements. This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All statements other than statements of historical fact included in this presentation are forward-looking statements, including, but not limited to, the Company's financial re ...

Acquisition of Ask Sage - BigBear.ai announced the acquisition of Ask Sage, an advanced generative-AI platform tailored for government agencies and highly regulated industries[11, 13] - Ask Sage's ARR grew 6X from '24-'25 and currently serves 16,000 government teams[13] - Ask Sage offers a secure platform for AI use in USG/DoD, reliable data and system connectivity, a marketplace for AI-powered tools, and services for custom AI apps[26] - Synergies between Ask Sage and BigBear.ai include cross-selling, customer expansion, tech integration, and go-to-market strategies[28] Financial Highlights (Q3 2025) - The company reported a record ending cash and investments balance of $715 million[33, 34] - The company had a net positive cash and investments position of almost $575 million as of the end of Q3[34] - For the three months ended September 30, 2025, net loss was $2521 thousand, compared to a net loss of $15135 thousand for the three months ended September 30, 2024[40] - For the three months ended September 30, 2025, Adjusted EBITDA was $(9401) thousand[40] - Revenues for the three months ended September 30, 2025 were $33143 thousand with a gross margin of 22.4% and an adjusted gross margin of 27.7%[43] Strategic Focus - The company focuses on disruptive AI software for national security, smart & secure travel & trade, and dual-use platform-level AI[18, 19]

Core Insights - Ready Capital Corporation reported a GAAP loss per common share from continuing operations of $(0.13) and a distributable loss per common share of $(0.94) for the quarter ended September 30, 2025 [1][22] - The company is focused on restoring financial health through decisive exit strategies for underperforming loans and risk management of upcoming debt maturities, aiming for balance sheet stability and profitability [2] Financial Performance - The company reported LMM commercial real estate originations of $139 million and Small Business Lending loan originations of $283 million, which included $173 million of Small Business Administration 7(a) loans [6] - The book value of common stock was $10.28 per share as of September 30, 2025 [6] - The company completed two portfolio sales consisting of 217 loans with an unpaid principal balance of $758 million for net proceeds of $109 million [6] Non-GAAP Financial Information - Distributable earnings, a non-GAAP measure, is defined as net income adjusted for various unrealized gains and losses, providing greater transparency into financial performance [3][4] - The calculation of distributable earnings excludes unrealized gains and losses on mortgage-backed securities retained as part of the loan origination business, as these are considered fundamental to ongoing performance [5] Income Statement Highlights - For the three months ended September 30, 2025, the company reported net interest income before provision for loan losses of $10,520 thousand, with a net loss from continuing operations of $(16,947) thousand [22][23] - Total non-interest income was $74,914 thousand, while total non-interest expense was $74,339 thousand, resulting in a loss from continuing operations before income taxes of $(26,882) thousand [22][23] Balance Sheet Overview - As of September 30, 2025, total assets were $8,332,101 thousand, with total liabilities of $6,448,542 thousand, resulting in stockholders' equity of $1,875,198 thousand [20][21] - The company had cash and cash equivalents of $147,505 thousand and loans net of $4,360,501 thousand [20]

Company Overview - As of September 30, 2025, CareTrust REIT's real estate portfolio has grown to 390 net-leased healthcare properties across 31 states and the United Kingdom, consisting of 35,687 operating beds/units[15] - CareTrust REIT also had 23 other real estate related investments related to 143 healthcare properties across 17 states and the United Kingdom, consisting of 14,082 operating beds/units and one financing receivable related to 46 properties in one state consisting of 3,820 operating beds/units[15] - The company's total investments reached $4,812.044 million, with a current yield of 9.7%[29] Portfolio Composition - Skilled Nursing Facilities (SNF) constitute 46.9% of the total investment, amounting to $2,255.078 million with a current yield of 10.6%[29] - UK Care Homes represent 19.3% of the total investment, totaling $930.768 million with a current yield of 7.4%[29] - Multi-Service Campuses account for 10.5% of the total investment, with a value of $503.626 million and a current yield of 9.7%[29] Financial Performance - For the three months ended September 30, 2025, the company reported rental income of $104.265 million[51] - Net income attributable to CareTrust REIT, Inc for the three months ended September 30, 2025, was $74.901 million, or $0.35 per share on a diluted basis[51] - Normalized FFO attributable to CareTrust REIT, Inc for the quarter ended September 30, 2025, was $94.677 million[53] Tenant Diversification - The Ensign Group is the largest tenant, contributing 24.8% of total rent with $92.102 million[32] - The top 5 tenants account for 55.7% of total rent, amounting to $207.260 million[32]

Q3 2025 Performance - Enovis reported a net sales increase to $549 million, a +9% growth, with +7% organic growth[17,8] - Reconstructive segment sales reached $258 million, showing +12% year-over-year growth and +9% organic growth[10] - Prevention & Recovery (P&R) segment sales were $291 million, with +6% year-over-year growth and +4% organic growth[15] - Adjusted gross profit increased to $331 million, resulting in a margin of 603%, compared to $298 million and 589% respectively in Q3 2024[17] - Adjusted EBITDA was $95 million, with a margin of 173%, compared to $90 million and 179% respectively in Q3 2024[17] - Adjusted EPS increased to $075, compared to $073 in Q3 2024[17] Full Year 2025 Outlook - Enovis anticipates full year reported revenue between $224 billion and $227 billion[23] - The company projects adjusted EBITDA between $395 million and $405 million[23] - Enovis estimates adjusted EPS to be between $310 and $325[23] Strategic Actions - Enovis divested its Footcare business, which represented 48% of Prevention and Recovery and 24% of Enovis revenues, impacting Q4 2025 revenue guidance by approximately $15 million[20] - The total transaction value for the Footcare divestiture is up to $60 million, including an upfront cash payment of $45 million and milestone payments up to $15 million[22]